Previous 10 | Next 10 |
Chinnapong/iStock via Getty Images Massachusetts-based clinical-stage Cue Biopharma (CUE) announced the dosing of the first patient in Part B expansion phase of its Phase 1 study for CUE-101 as monotherapy at the recommended Phase 2 dose of 4mg/kg. The multi-center, open-label study...
Chinnapong/iStock via Getty Images Massachusetts-based clinical-stage Cue Biopharma (CUE) announced the dosing of the first patient in Part B expansion phase of its Phase 1 study for CUE-101 as monotherapy at the recommended Phase 2 dose of 4mg/kg. The multi-center, open-label study...
CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, ann...
CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, ann...
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, anno...
Cue Biopharma, Inc. (CUE) Q1 2021 Earnings Conference Call May 17, 2021, 04:30 PM ET Company Participants George Zavoico - VP, IR & Corporate Development Daniel Passeri - CEO & Director Anish Suri - President & Chief Scientific Officer Ken Pienta - Acting Chief Medical Officer Mat...
Cue Biopharma (CUE): Q1 GAAP EPS of -$0.41 misses by $0.02.Revenue of $1.55M (+72.2% Y/Y) beats by $0.94M.“We finished the first quarter of 2021 in a solid financial position which was further strengthened by the deployment of our at-the-market common stock facility in April that enabl...
CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, provided a business an...
Gainers: Protagenic Therapeutics (PTIX) +67%.Obalon Therapeutics (OBLN) +57%.Precipio (PRPO) +35%.Cue Biopharma (CUE) +31%.SemiLEDs (LEDS) +28%.CKX Lands (CKX) +27%.Tecnoglass (TGLS) +24%.Soliton (SOLY) +24%.Party City Holdco (PRTY) +19%.uCloudlink (UCL) +16%.Losers: Rekor...
Cue Biopharma (CUE) gains 8% premarket after announcing interim clinical data from its ongoing Phase 1a/1b monotherapy study of CUE-101 as second-line treatment for patients with human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSC...
News, Short Squeeze, Breakout and More Instantly...
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company anticipates annualized capital and workforce requirements to be reduced by approximately 25...
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and KEYTRUDA ® (pembrolizumab) Median overall survival (mOS) of 20.8 months in second...
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it will participate in two investor confe...